BioIntelliSense has received approval from the US Food and Drug Administration (FDA) for its BioButton Multi-Patient wearable and BioDashboard system for continuous patient monitoring.
The rechargeable and reusable device BioButton is designed to enhance virtual care programmes in hospitals.
Go deeper with GlobalData
It is part of the company’s portfolio, aimed at automating vital sign collection across various healthcare settings and facilitating hospital-level care at home.
The BioDashboard clinical intelligence system offers data-driven exception management, enabling scalable, automated notifications personalised for each patient.
This allows clinicians to monitor numerous patients concurrently, making proactive clinical decisions through a configurable dashboard view.
The BioButton Multi-Patient wearable and BioDashboard system marks a shift from episodic to continuous vital sign trend monitoring, aiding clinicians in detecting significant changes in patient physiology for earlier intervention and better outcomes.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe comprehensive inpatient monitoring solution from BioIntelliSense, powered by the new BioButton wearables, charging stations, BioHub Wi-Fi gateways, BioCloud data analytics, and the BioDashboard clinical intelligence system offers a scalable continuous care model.
It aims to improve patient safety and clinical workflow efficiencies by reducing manual tasks related to spot-checking vital sign measurements along with documentation. This efficiency allows for better prioritisation of care and resource allocation to patients requiring more hands-on attention.
BioIntelliSense founder and CEO Dr James Mault said: “We are advancing a new standard of care by automating the capture of thousands of multiparameter measurements each day and for every general care patient throughout their inpatient stay and now the BioButton Multi-Patient wearable is conveniently rechargeable with its own dedicated in-facility charging station.
“The introduction of the rechargeable and reusable BioButton Multi-Patient wearable, combined with the BioDashboard clinical intelligence solution, provides health systems nationwide unprecedented economies of scale in making continuous care more affordable and accessible for every patient that is admitted to the hospital.”
BioIntelliSense’s BioButton and BioDashboard System is a cloud-based platform that extends from in-hospital to home care.
